Literature DB >> 17118370

Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation.

Yoshino Matsuo1, Shin-ichiro Miura, Akira Kawamura, Yoshinari Uehara, Kerry-Anne Rye, Keijiro Saku.   

Abstract

Reconstituted high-density lipoprotein (rHDL) has been shown to produce a rapid regression of atherosclerosis in animal models and humans. Sphingosine-1-phosphate (S1P), which is a bioactive lipid in HDL, plays a role in mitogenesis, endothelial cell motility, and cell survival, as well as organization and differentiation into a vessel. In this study, we examined the direct role of a newly developed rHDL, [POPC(1-palmitoyl-2-oleoyl phosphatidylcholine)/S1P/apolipoproteinA-I(A-I)]rHDL containing S1P in tube formation in endothelial cells (ECs) as well as cholesterol efflux in macrophage. The effect of (POPC/S1P/A-I)rHDL on cholesterol efflux in macrophage was similar to that of conventional rHDL, (POPC/A-I)rHDL. In addition, (POPC/S1P/A-I)rHDL induced EC proliferation through the activation of phospho-Akt and phospho-extracellular-signal-regulated kinases (p-ERK) 1/2 and EC tube formation, and this effect was blocked by inhibitors of Akt, ERK and endothelial nitric-oxide synthase (eNOS). In addition, (POPC/S1P/A-I)rHDL-induced p-ERK1/2 activation and EC tube formation can be mainly attributed to S1P-stimulated signaling through S1P2 and S1P3 as determined by an anti-sense strategy. In conclusion, (POPC/S1P/A-I)rHDL induces cholesterol efflux independently of S1P but has additional S1P-mediated effects on EC tube formation mediated by Akt/ERK/NO through S1P2 and S1P3. In the future, these new discs may be useful for the treatment of atherosclerotic and ischemic cardiovascular disease, such as acute coronary syndrome and atherosclerosis obliterans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118370     DOI: 10.1016/j.atherosclerosis.2006.10.020

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  12 in total

1.  HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.

Authors:  Yoshitaka Sekine; Kazuhiro Suzuki; Alan T Remaley
Journal:  Prostate       Date:  2010-10-26       Impact factor: 4.104

2.  Plasma gelsolin modulates cellular response to sphingosine 1-phosphate.

Authors:  Robert Bucki; Alina Kulakowska; Fitzroy J Byfield; Malgorzata Zendzian-Piotrowska; Marcin Baranowski; Michal Marzec; Jessamine P Winer; Nicholas J Ciccarelli; Jan Górski; Wieslaw Drozdowski; Robert Bittman; Paul A Janmey
Journal:  Am J Physiol Cell Physiol       Date:  2010-09-01       Impact factor: 4.249

Review 3.  Unraveling the complexities of the HDL lipidome.

Authors:  Anatol Kontush; Marie Lhomme; M John Chapman
Journal:  J Lipid Res       Date:  2013-03-30       Impact factor: 5.922

Review 4.  "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.

Authors:  Kazuaki Takabe; Steven W Paugh; Sheldon Milstien; Sarah Spiegel
Journal:  Pharmacol Rev       Date:  2008-06-13       Impact factor: 25.468

Review 5.  High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway.

Authors:  Miguel A Frias; Sandrine Lecour; Richard W James; Sarah Pedretti
Journal:  JAKSTAT       Date:  2012-04-01

6.  Nanobiotechnology applications of reconstituted high density lipoprotein.

Authors:  Robert O Ryan
Journal:  J Nanobiotechnology       Date:  2010-12-01       Impact factor: 10.435

7.  The impact of bioactive lipids on cardiovascular development.

Authors:  Alexander Kleger; Stefan Liebau; Qiong Lin; Götz von Wichert; Thomas Seufferlein
Journal:  Stem Cells Int       Date:  2011-08-02       Impact factor: 5.443

8.  High density lipoprotein stimulated migration of macrophages depends on the scavenger receptor class B, type I, PDZK1 and Akt1 and is blocked by sphingosine 1 phosphate receptor antagonists.

Authors:  Aishah Al-Jarallah; Xing Chen; Leticia González; Bernardo L Trigatti
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

9.  Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis.

Authors:  Gianpaolo Tibolla; Roberto Piñeiro; Daniela Chiozzotto; Ioanna Mavrommati; Ann P Wheeler; Giuseppe Danilo Norata; Alberico Luigi Catapano; Tania Maffucci; Marco Falasca
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

Review 10.  HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications.

Authors:  Bodo Levkau
Journal:  Front Pharmacol       Date:  2015-10-20       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.